Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
Identifieur interne : 000899 ( PubMed/Corpus ); précédent : 000898; suivant : 000900Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
Auteurs : Christopher M. Stone ; Randee Kastner ; Peter Steinmann ; Nakul Chitnis ; Marcel Tanner ; Fabrizio TediosiSource :
- BMJ global health [ 2059-7908 ] ; 2016.
Abstract
A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.
DOI: 10.1136/bmjgh-2015-000021
PubMed: 28588916
Links to Exploration step
pubmed:28588916Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</title>
<author><name sortKey="Stone, Christopher M" sort="Stone, Christopher M" uniqKey="Stone C" first="Christopher M" last="Stone">Christopher M. Stone</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kastner, Randee" sort="Kastner, Randee" uniqKey="Kastner R" first="Randee" last="Kastner">Randee Kastner</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Steinmann, Peter" sort="Steinmann, Peter" uniqKey="Steinmann P" first="Peter" last="Steinmann">Peter Steinmann</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chitnis, Nakul" sort="Chitnis, Nakul" uniqKey="Chitnis N" first="Nakul" last="Chitnis">Nakul Chitnis</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tanner, Marcel" sort="Tanner, Marcel" uniqKey="Tanner M" first="Marcel" last="Tanner">Marcel Tanner</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tediosi, Fabrizio" sort="Tediosi, Fabrizio" uniqKey="Tediosi F" first="Fabrizio" last="Tediosi">Fabrizio Tediosi</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:28588916</idno>
<idno type="pmid">28588916</idno>
<idno type="doi">10.1136/bmjgh-2015-000021</idno>
<idno type="wicri:Area/PubMed/Corpus">000899</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000899</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</title>
<author><name sortKey="Stone, Christopher M" sort="Stone, Christopher M" uniqKey="Stone C" first="Christopher M" last="Stone">Christopher M. Stone</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kastner, Randee" sort="Kastner, Randee" uniqKey="Kastner R" first="Randee" last="Kastner">Randee Kastner</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Steinmann, Peter" sort="Steinmann, Peter" uniqKey="Steinmann P" first="Peter" last="Steinmann">Peter Steinmann</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chitnis, Nakul" sort="Chitnis, Nakul" uniqKey="Chitnis N" first="Nakul" last="Chitnis">Nakul Chitnis</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tanner, Marcel" sort="Tanner, Marcel" uniqKey="Tanner M" first="Marcel" last="Tanner">Marcel Tanner</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tediosi, Fabrizio" sort="Tediosi, Fabrizio" uniqKey="Tediosi F" first="Fabrizio" last="Tediosi">Fabrizio Tediosi</name>
<affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">BMJ global health</title>
<idno type="ISSN">2059-7908</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28588916</PMID>
<DateCreated><Year>2017</Year>
<Month>06</Month>
<Day>07</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>08</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2059-7908</ISSN>
<JournalIssue CitedMedium="Print"><Volume>1</Volume>
<Issue>1</Issue>
<PubDate><Year>2016</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>BMJ global health</Title>
<ISOAbbreviation>BMJ Glob Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</ArticleTitle>
<Pagination><MedlinePgn>e000021</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjgh-2015-000021</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We extended an LF transmission model to track hydrocele and lymphoedema incidence in order to obtain estimates of the disability adjusted life years (DALYs) averted due to scaling up MDA over a period of 50 years. We then estimated the ICERs and the cost-effectiveness acceptability curves associated with different rates of MDA scale-up. Health systems savings were estimated by considering the averted morbidity, treatment-seeking behaviour and morbidity management costs. Gains in worker productivity were estimated by multiplying estimated working days lost as a result of morbidity with country-specific per-worker agricultural wages.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Our projections indicate that a massive scaling-up of MDA could lead to 4.38 million incremental DALYs averted over a 50-year time horizon compared to a scenario which mirrors current efforts against LF. In comparison to maintaining the current rate of progress against LF, massive scaling-up of MDA-pursuing LF eradication as soon as possible-was most likely to be cost-effective above a willingness to pay threshold of US$71.5/DALY averted. Intensified MDA scale-up was also associated with lower ICERs. Furthermore, this could result in health systems savings up to US$483 million. Extending coverage to all endemic areas could generate additional economic benefits through gains in worker productivity between US$3.4 and US$14.4 billion.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In addition to ethical and political motivations for scaling-up MDA rapidly, this analysis provides economic support for increasing the intensity of MDA programmes.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName>
<ForeName>Christopher M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kastner</LastName>
<ForeName>Randee</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Steinmann</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chitnis</LastName>
<ForeName>Nakul</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tanner</LastName>
<ForeName>Marcel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tediosi</LastName>
<ForeName>Fabrizio</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>04</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMJ Glob Health</MedlineTA>
<NlmUniqueID>101685275</NlmUniqueID>
<ISSNLinking>2059-7908</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Aug 06;3(8):e2874</RefSource>
<PMID Version="1">18716676</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2004 Aug;9(8):843-5</RefSource>
<PMID Version="1">15303987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2000 Dec 1;77(3):287-94</RefSource>
<PMID Version="1">11114391</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2010 Jun 01;4(6):e708</RefSource>
<PMID Version="1">20532228</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2000 Apr;13(2):207-22</RefSource>
<PMID Version="1">10755998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2011 Jan 25;8(1):e1000412</RefSource>
<PMID Version="1">21311585</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3393</RefSource>
<PMID Version="1">25501002</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Decis Making. 1990 Jul-Sep;10(3):212-4</RefSource>
<PMID Version="1">2115096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319</RefSource>
<PMID Version="1">25412180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2004 Aug;20(8):347-51</RefSource>
<PMID Version="1">15246314</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2016 Feb 1;62(3):334-341</RefSource>
<PMID Version="1">26486704</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2006 May;11(5):718-28</RefSource>
<PMID Version="1">16640625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120144</RefSource>
<PMID Version="1">23798692</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Dec 15;380(9859):2129-43</RefSource>
<PMID Version="1">23245605</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2015 Oct 09;9(10):e0004147</RefSource>
<PMID Version="1">26451729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Dec 15;380(9859):2197-223</RefSource>
<PMID Version="1">23245608</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3328</RefSource>
<PMID Version="1">25502758</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2007 Nov 21;1(2):e128</RefSource>
<PMID Version="1">18060080</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Aug 22;369(8):745-53</RefSource>
<PMID Version="1">23964936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Popul Health Metr. 2012 Sep 12;10(1):19</RefSource>
<PMID Version="1">22967055</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2013 Nov 07;7(11):e2446</RefSource>
<PMID Version="1">24244762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 2015 Apr;105(4):629-36</RefSource>
<PMID Version="1">25713967</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2002 Apr;15(2):223-46</RefSource>
<PMID Version="1">11932231</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Aug 13;3(8):e2936</RefSource>
<PMID Version="1">18698350</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Epidemiol Infect. 2000 Jun;124(3):529-41</RefSource>
<PMID Version="1">10982078</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Jun 12;10(6):e0130603</RefSource>
<PMID Version="1">26070135</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Nov 6;376(9752):1604-15</RefSource>
<PMID Version="1">21035839</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 2009;27(11):903-17</RefSource>
<PMID Version="1">19888791</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trop Geogr Med. 1980 Sep;32(3):259-64</RefSource>
<PMID Version="1">7210162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 May 07;10(5):e0123853</RefSource>
<PMID Version="1">25950443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008 Oct 08;2(10):e317</RefSource>
<PMID Version="1">18841205</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Apr 21;369(9570):1363-71</RefSource>
<PMID Version="1">17448822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jun 27;373(9682):2192-3</RefSource>
<PMID Version="1">19582890</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2000 Sep 18;76(2):197-9</RefSource>
<PMID Version="1">10936580</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2011 Dec 30;29 Suppl 4:D70-3</RefSource>
<PMID Version="1">22188936</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<CoiStatement>Competing interests: MT serves as board member for DNDi, and serves on the scientific advisory board of the Novartis Institute for Tropical Diseases.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>12</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>01</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>01</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28588916</ArticleId>
<ArticleId IdType="doi">10.1136/bmjgh-2015-000021</ArticleId>
<ArticleId IdType="pii">bmjgh-2015-000021</ArticleId>
<ArticleId IdType="pmc">PMC5321305</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000899 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000899 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:28588916 |texte= Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28588916" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |